Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2022 Oct;10(10):e005636.
doi: 10.1136/jitc-2022-005636.

Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)

Marie Wislez  1 , Julien Mazieres  2 , Armelle Lavole  3 , Gérard Zalcman  4 , Olivier Carre  5 , Thomas Egenod  6 , Raffaele Caliandro  7 , Catherine Dubos-Arvis  8 , Gaelle Jeannin  9 , Olivier Molinier  10 , Marie-Ange Massiani  11 , Alexandra Langlais  12 , Franck Morin  13 , Francoise Le Pimpec Barthes  14 , Laurent Brouchet  15 , Jalal Assouad  16 , Bernard Milleron  13 , Diane Damotte  17 , Martine Antoine  18 , Virginie Westeel  19
Affiliations
Multicenter Study

Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)

Marie Wislez et al. J Immunother Cancer. 2022 Oct.

Abstract

Background: The IONESCO (IFCT-1601) trial assessed the feasibility of neoadjuvant durvalumab, for early-stage resectable non-small-cell lung cancer (NSCLC).

Methods: In a multicenter, single-arm, phase II trial, patients with IB (≥4 cm)-IIIA, non-N2, resectable NSCLC received three doses of durvalumab (750 mg every 2 weeks) and underwent surgery between 2 and 14 days after the last infusion. The primary endpoint was the complete surgical resection rate. Secondary endpoints included tumor response rate, major histopathological response (MPR: ≤10% remaining viable tumor cells), disease-free survival (DFS), overall survival (OS), durvalumab-related safety, and 90-day postoperative mortality (NCT03030131).

Results: Forty-six patients were eligible (median age 60.9 years); 67% were male, 98% were smokers, and 41% had squamous cell carcinoma. Regarding tumor response, 9% had a partial response, 78% had stable disease, and 13% had progressive disease. Among the operated patients (n=43), 41 achieved complete resection (89%, 95% CI 80.1% to 98.1%)), and eight achieved MPR (19%). The 12-month median OS and DFS rates were 89% (95% CI 75.8% to 95.3%) and 78% (95% CI 63.4% to 87.7%), respectively (n=46). The median follow-up was 28.4 months (12.8-41.1). All patients in whom MPR was achieved were disease-free at 12 months compared to only 11% of those with >10% residual tumor cells (p=0.04). No durvalumab-related serious or grade 3-5 events were reported. The unexpected 90-day postoperative mortality of four patients led to premature study termination. None of these four deaths was considered secondary to direct durvalumab-related toxicity.

Conclusions: Neoadjuvant durvalumab given as monotherapy was associated with an 89% complete resection rate and an MPR of 19%. Despite an unexpectedly high rate of postoperative deaths, which prevented us from completing the trial, we were able to show a significant association between MPR and DFS.

Keywords: Biomarkers, Tumor; Immunotherapy; Lung Neoplasms; Programmed Cell Death 1 Receptor.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Marie Wislez, reports grants from Astra-Zeneca, honoraria for speaker’s bureau from Roche, Bristol Myers Squibb and Boehringer Ingelheim, participation on a Data Safety Monitoring Board or Advisory Board from Astra-Zeneca, Merck Sharp and Dohme and Novartis, non-financial interests from Astra-Zeneca, Bristol Myers Squibb, Merck Sharp and Dohme, Novartis, Lilly Merck KgA, Merus, GlaxoSmithKline and Amgen, outside the submitted work. Julien Mazières reports honoraria for lectures from Bristol Myers Squibb, Roche Genentech, Astra-Zeneca and Merck Sharp and Dohme, outside the submitted work. Gérard Zalcman reports grants from Roche and Bristol Myers Squibb, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Astra-Zeneca and Bristol Myers Squibb, support for attending meetings and/or travel from Astra-Zeneca, Abbvie, Bristol Myers Squibb and Pfizer, participation on a Data Safety Monitoring Board or Advisory Board from Astra-Zeneca, Inventiva, Da Volterra and Bristol Myers Squibb, outside the submitted work. Olivier Molinier reports participation on a Data Safety Monitoring Board or Advisory Board from Astra-Zeneca, outside the submitted work. Virginie Westeel reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Astra-Zeneca, Bristol Myers Squibb, Merck Sharp and Dohme and Roche, Support for attending meetings and/or travel from Astra-Zeneca, Bristol Myers Squibb, Merck Sharp and Dohme, Pfizer and Roche, Participation on a Data Safety Monitoring Board or Advisory Board from Astra-Zeneca, Bristol Myers Squibb, Merck Sharp and Dohme, Takeda and Roche, outside the submitted work. All other authors have nothing to disclose.

Figures

Figure 1
Figure 1
CONSORT flowchart of the IONESCO trial
Figure 2
Figure 2
Survival probability depends on achieving a major histopathological response. OS and DFS are shown for 46 durvalumab-treated patients (A, B, respectively). The median follow-up was 28.4 months. (C, D) shows the association between MPR and OS (C) and between MPR and DFS (D). Regarding RVT, the category (0%–10%) corresponds to patients who achieved MPR; the category >10% corresponds to patients who did not achieve MPR. DFS, disease-free survival; MPR, major pathological response; NR, not reported; OS, overall survival; RVT, residual viable tumor cells (%).
See this image and copyright information in PMC

References

    1. Wakelee HA, Altorki NK, Zhou C, et al. . IMpower010: primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). JCO 2021;39:8500. 10.1200/JCO.2021.39.15_suppl.8500 - DOI
    1. Paz-Ares L, O'Brien MER, Mauer M, et al. . VP3-2022: pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study. Annals of Oncology 2022;33:451–3. 10.1016/j.annonc.2022.02.224 - DOI
    1. Forde PM, Spicer J, Lu S, et al. . Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med 2022;386:1973–85. 10.1056/NEJMoa2202170 - DOI - PMC - PubMed
    1. Liu J, Blake SJ, Yong MCR, et al. . Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov 2016;6:1382–99. 10.1158/2159-8290.CD-16-0577 - DOI - PubMed
    1. Hellmann MD, Chaft JE, William WN, et al. . Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol 2014;15:e42–50. 10.1016/S1470-2045(13)70334-6 - DOI - PMC - PubMed

Publication types

Substances

Associated data